Streetbeat News

Analyst Ratings

RNAC

HC Wainwright & Co. analyst Mitchell Kapoor has reiterated a Buy rating on Cartesian Therapeutics (NASDAQ:RNAC) and maintained a $2 price target.

Portfolio Pulse from Benzinga Newsdesk

March 11, 2024 | 10:47 am

YMM

Barclays analyst Jiong Shao maintains an Equal-Weight rating on Full Truck Alliance Co (YMM) and lowers the price target from $8 to $6.

Portfolio Pulse from Benzinga Newsdesk

March 11, 2024 | 10:47 am

MLTX

Needham analyst Serge Belanger has reiterated a Buy rating on MoonLake (NASDAQ:MLTX) and maintained a $66 price target.

Portfolio Pulse from Benzinga Newsdesk

March 11, 2024 | 10:46 am

XPO

JP Morgan analyst Brian Ossenbeck has maintained an Overweight rating on XPO Logistics (NYSE:XPO) and increased the price target from $122 to $140.

Portfolio Pulse from Benzinga Newsdesk

March 11, 2024 | 10:45 am

MGNX

HC Wainwright & Co. analyst Robert Burns maintains a Neutral rating on Macrogenics (NASDAQ:MGNX) and raises the price target from $14 to $16.

Portfolio Pulse from Benzinga Newsdesk

March 11, 2024 | 10:43 am

ZYME

HC Wainwright & Co. analyst Robert Burns maintains a Neutral rating on Zymeworks (NASDAQ:ZYME) and raises the price target from $8 to $10.

Portfolio Pulse from Benzinga Newsdesk

March 11, 2024 | 10:41 am

ALXO

HC Wainwright & Co. analyst Swayampakula Ramakanth maintains a Buy rating on ALX Oncology Holdings (NASDAQ:ALXO) and raises the price target from $17.5 to $20.

Portfolio Pulse from Benzinga Newsdesk

March 11, 2024 | 10:39 am

NYCB

Keefe, Bruyette & Woods analyst Christopher Mcgratty has maintained a 'Market Perform' rating on New York Community (NYCB) but has lowered the price target from $7.5 to $3.75.

Portfolio Pulse from Benzinga Newsdesk

March 11, 2024 | 10:38 am

JANX

HC Wainwright & Co. analyst Swayampakula Ramakanth maintains a Buy rating on Janux Therapeutics (NASDAQ:JANX) and raises the price target from $35 to $50.

Portfolio Pulse from Benzinga Newsdesk

March 11, 2024 | 10:38 am

XEL

Xcel Energy's stock (XEL) trades higher following an upgrade from Wolfe Research, moving from Peer Perform to Outperform with a new price target of $58.

Portfolio Pulse from Benzinga Newsdesk

March 11, 2024 | 10:35 am